The UK government has announced new cyber laws designed to strengthen the UK’s defences against cyberattacks on essential services, such as the NHS, water, transport, and energy networks.
Chief Scientist at Dynamic Object Language Labs Inc, Dr Paul Robertson explains how autonomous AI systems are key to achieving synergy between humans and robotics that can work together as a team.
Philip Turvey, executive director at Anglia Research, outlines why businesses need to use the return to normality as an opportunity to draw a line under unethical practice in 2021.
Ivan Harding, Co-Founder & CEO at Applaud, explores why delivering a consistent employee experience is key for recruitment during a time of uncertainty.
Mauro Petriccione, Directorate-General for Climate Action at the European Commission, illustrates Europe’s plans for a green recovery following the COVID-19 pandemic.
Dr Charu Kaushic, Chair of GloPID-R, and Dr Geneviève Boily-Larouche, CIHR Institute of Infection and Immunity, provide a perspective on pandemic preparedness and response, including lessons learned for global coordination among research funders.
In a year of COVID-19-related death and worry, loneliness has been an accompanying sensation, constant and stubborn - now, scientists believe they know how loneliness changes brain structure.
Robert B Stone and Jordan M Berg, of the Civil, Mechanical and Manufacturing Innovation Division at the U.S. National Science Foundation, chart precisely how engineering research improves people’s lives.
Mark Grayston, Head of Product Marketing at Mitsubishi Electric, discusses the intrinsic link between air quality and health in our built environments.
Richard Cox, managing director of Langley Business Systems, gives an overview of the main ways hospitality businesses can maximise technology to navigate through the pandemic and ensure customers feel safe when visiting their premises.
Gill McAteer, head of employment law at Citation, details the necessary changes needed to improve recruitment and retention in the nursery sector to fit the 'new normal'.
Jean Van Rampelbergh PhD, VP Clinical & Regulatory at Imcyse SA, introduces ImotopesTM a cutting-edge immunotherapy science with an excellent safety profile that could cure Type 1 diabetes or drastically change treatment options.
